REGULATORY
Shipments of Kaketsuken’s Hep B Vaccine Likely to Resume Early Next Year
The Ministry of Health, Labor and Welfare (MHLW) is expected to allow the shipment of the Chemo-Sero-Therapeutic Research Institute’s (Kaketsuken) hepatitis B vaccine Bimmugen in early next year to avert supply shortages. The possible plan was suggested on December 17…
To read the full story
Related Article
- MHLW Allows Shipment of Kaketsuken’s Hep A, B Vaccines
February 2, 2016
REGULATORY
- Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
- Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
- Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
- Japan Diet Begins Deliberations on Immunization Act Revision
June 25, 2026
- Expert Calls for AMR Ecosystem to Boost Japan Antibiotic Innovation
June 25, 2026
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…





